A DNA vaccine targeting TcdA and TcdB induces protective immunity against Clostridium difficile.
BMC Infect Dis
; 16(1): 596, 2016 Oct 22.
Article
em En
| MEDLINE
| ID: mdl-27770789
ABSTRACT
BACKGROUND:
Clostridium difficile-associated disease (CDAD) constitutes a great majority of hospital diarrhea cases in industrialized countries and is induced by two types of large toxin molecules toxin A (TcdA) and toxin B (TcdB). Development of immunotherapeutic approaches, either active or passive, has seen a resurgence in recent years. Studies have described vaccine plasmids that express either TcdA and/or TcdB receptor binding domain (RBD). However, the effectiveness of one vector encoding both toxin RBDs against CDAD has not been evaluated.METHODS:
In the study, we constructed highly optimized plasmids to express the receptor binding domains of both TcdA and TcdB from a single vector. The DNA vaccine was evaluated in two animal models for its immunogenicity and protective effects.RESULTS:
The DNA vaccine induced high levels of serum antibodies to toxin A and/or B and demonstrated neutralizing activity in both in vitro and in vivo systems. In a C. difficile hamster infection model, immunization with the DNA vaccine reduced infection severity and conferred significant protection against a lethal C. difficile strain.CONCLUSIONS:
This study has demonstrated a single plasmid encoding the RBD domains of C. difficile TcdA and TcdB as a DNA vaccine that could provide protection from C. difficile disease.Palavras-chave
Texto completo:
1
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Proteínas de Bactérias
/
Toxinas Bacterianas
/
Vacinas Bacterianas
/
Clostridioides difficile
/
Vacinas de DNA
/
Enterotoxinas
Limite:
Animals
Idioma:
En
Ano de publicação:
2016
Tipo de documento:
Article